Last reviewed · How we verify
KNT-0916
At a glance
| Generic name | KNT-0916 |
|---|---|
| Sponsor | KinoTeck Therapeutics Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KNT-0916 CI brief — competitive landscape report
- KNT-0916 updates RSS · CI watch RSS
- KinoTeck Therapeutics Co., Ltd portfolio CI